Literature DB >> 31639839

Diabetic Neuropathy.

Elina Zakin1, Rory Abrams2, David M Simpson2.   

Abstract

Diabetes mellitus is becoming increasingly common worldwide. As this occurs, there will be an increase in the prevalence of known comorbidities from this disorder of glucose metabolism. One of the most disabling adverse comorbidities is diabetic neuropathy. The most common neuropathic manifestation is distal symmetric polyneuropathy, which can lead to sensory disturbances, including diminished protective sense, making patients prone to foot injuries. However, focal, multifocal, and autonomic neuropathies are also common. Diabetic nerve pain and Charcot osteoarthropathy are advanced neuropathic conditions that portend a severe deterioration in quality of life. To combat these symptoms, along with glycemic control and establishment of health care systems to educate and support patients with the complexities of diabetes, there are pharmacologic remedies to ameliorate the neurologic symptoms. Several guidelines and review boards generally recommend the use of tricyclic antidepressants, serotonin/norepinephrine-reuptake inhibitors, α-2-delta ligands, and anticonvulsants as medications to improve painful diabetic neuropathy and quality of life. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2019        PMID: 31639839     DOI: 10.1055/s-0039-1688978

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  18 in total

1.  A Real-World Analysis of High-Frequency 10 kHz Spinal Cord Stimulation for the Treatment of Painful Diabetic Peripheral Neuropathy.

Authors:  Jeffrey L Chen; Andrew W Hesseltine; Sara E Nashi; Shawn M Sills; Tory L McJunkin; Sandeep Patil; Manish Bharara; David L Caraway; Elizabeth S Brooks
Journal:  J Diabetes Sci Technol       Date:  2021-11-29

2.  Does [99mTc]-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) soft tissue uptake allow the identification of patients with the diagnosis of cardiac transthyretin-related (ATTR) amyloidosis with higher risk for polyneuropathy?

Authors:  Tim Wollenweber; Elisabeth Kretschmer-Chott; Raphael Wurm; Sazan Rasul; Oana Kulterer; Rene Rettl; Franz Duca; Diana Bonderman; Kurt-Wolfram Sühs; Marcus Hacker; Tatjana Traub-Weidinger
Journal:  J Nucl Cardiol       Date:  2022-07-11       Impact factor: 3.872

Review 3.  Neuroinflammation Involved in Diabetes-Related Pain and Itch.

Authors:  Xiao-Xia Fang; Heng Wang; Hao-Lin Song; Juan Wang; Zhi-Jun Zhang
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

4.  Expression and Mechanism of TXNIP/NLRP3 Inflammasome in Sciatic Nerve of Type 2 Diabetic Rats.

Authors:  Le Han; Guangxia Xi; Na Guo; Jing Guo; Qingfeng Rong
Journal:  Dis Markers       Date:  2022-07-08       Impact factor: 3.464

Review 5.  The Endocannabinoid System as a Therapeutic Target in Diabetic Peripheral Neuropathic Pain: A Review.

Authors:  Amina M Bagher
Journal:  J Microsc Ultrastruct       Date:  2021-05-24

6.  (Pre)diabetes, glycemia, and daily glucose variability are associated with retinal nerve fiber layer thickness in The Maastricht Study.

Authors:  Frank C T van der Heide; Yuri D Foreman; Iris W M Franken; Ronald M A Henry; Abraham A Kroon; Pieter C Dagnelie; Simone J P M Eussen; Tos T J M Berendschot; Jan S A G Schouten; Carroll A B Webers; Miranda T Schram; Carla J H van der Kallen; Marleen M J van Greevenbroek; Anke Wesselius; Casper G Schalkwijk; Nicolaas C Schaper; Martijn C G J Brouwers; Coen D A Stehouwer
Journal:  Sci Rep       Date:  2022-10-22       Impact factor: 4.996

Review 7.  Prospects for the application of transcranial magnetic stimulation in diabetic neuropathy.

Authors:  Xi Xu; Dong-Sheng Xu
Journal:  Neural Regen Res       Date:  2021-05       Impact factor: 5.135

8.  The Association of Fasting C-peptide with Corneal Neuropathy in Patients with Type 2 Diabetes.

Authors:  Anju Zuo; Chuan Wang; Lili Li; Jingru Qu; Juan Cao; Li Chen; Solomon Tesfaye; Wenjuan Li; Xinguo Hou
Journal:  J Diabetes Res       Date:  2020-12-02       Impact factor: 4.011

9.  Protective effects of antidepressant citalopram against abnormal APP processing and amyloid beta-induced mitochondrial dynamics, biogenesis, mitophagy and synaptic toxicities in Alzheimer's disease.

Authors:  Arubala P Reddy; Xiangling Yin; Neha Sawant; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2021-05-29       Impact factor: 6.150

10.  Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimer's disease.

Authors:  Arubala P Reddy; Neha Sawant; Hallie Morton; Sudhir Kshirsagar; Lloyd E Bunquin; Xiangling Yin; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2021-05-28       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.